and the Recombinate Study Group. Safety, efficacy and inhibitor risk of recombinant factor VIII (Recombinate) in a cohort of previously untreated patients (PUPs) with severe hemophilia A - Bray, G L; Courter, S; Lynes, M; Lee, M; Gomperts, E (Thromb Haemost, 1993)